Chahin Michael, Krishnan Nithya, Matthews-Hew Trevanne, Hew Jason, Pham Dat
Internal Medicine, University of Florida College of Medicine - Jacksonville, Jacksonville, USA.
Hematology and Oncology, University of Florida College of Medicine - Jacksonville, Jacksonville, USA.
Cureus. 2020 Jul 28;12(7):e9437. doi: 10.7759/cureus.9437.
Lung cancer is a worldwide concern and is the leading cause of cancer-related death in the United States. Adenocarcinoma is the most common type of non-small cell lung cancer; however, unlike other types of lung cancer this disease is often seen in light tobacco smokers and non-smokers. The presence of driver mutations, such as the epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein-like 4 (EML-4)-anaplastic lymphoma kinase (ALK) rearrangement, appears to be more common in these patients. The presence of the ALK mutation provides a target for ALK-inhibiting agents, such as alectinib. Routine testing for driver mutations is the standard of care in the management of advanced non-small cell lung cancer. Lung cancer frequently metastasizes to distant sites such as the bone, brain, and the adrenal glands, but rarely to the ovaries. We present a young, female, patient who complained of shortness of breath and was found to have pulmonary emboli, extensive lymphadenopathy, and a right ovarian mass. Initial pathology from a cervical lymph node favored a gastrointestinal or an ovarian malignancy. However, immunohistochemical staining ultimately suggested an occult lung adenocarcinoma primary with ovarian metastasis. She had a left oophorectomy that demonstrated similar findings and was positive for the ALK mutation. She was treated with alectinib with good response though ultimately died from her disease. This case demonstrates the rare finding of an ALK-mutated lung adenocarcinoma with ovarian metastasis and, to our knowledge, it is the first with an occult lung adenocarcinoma primary. Driver mutation testing should be considered in metastasis from an occult primary when a pulmonary malignancy is suspected.
肺癌是一个全球性问题,也是美国癌症相关死亡的主要原因。腺癌是最常见的非小细胞肺癌类型;然而,与其他类型的肺癌不同,这种疾病常见于轻度吸烟者和不吸烟者。驱动基因突变的存在,如表皮生长因子受体(EGFR)和棘皮动物微管相关蛋白样4(EML-4)-间变性淋巴瘤激酶(ALK)重排,在这些患者中似乎更为常见。ALK突变的存在为ALK抑制剂(如阿来替尼)提供了靶点。驱动基因突变的常规检测是晚期非小细胞肺癌管理中的标准治疗方法。肺癌经常转移到远处部位,如骨骼、大脑和肾上腺,但很少转移到卵巢。我们报告一名年轻女性患者,她主诉呼吸急促,被发现患有肺栓塞、广泛淋巴结病和右侧卵巢肿块。颈部淋巴结的初始病理结果倾向于胃肠道或卵巢恶性肿瘤。然而,免疫组化染色最终提示为隐匿性原发性肺腺癌伴卵巢转移。她接受了左卵巢切除术,结果相似,ALK突变呈阳性。她接受了阿来替尼治疗,反应良好,但最终死于该疾病。本病例显示了罕见的ALK突变肺腺癌伴卵巢转移,据我们所知,这是首例隐匿性原发性肺腺癌。当怀疑肺部恶性肿瘤时,对于隐匿性原发灶转移应考虑进行驱动基因突变检测。